NCT06891885View on ClinicalTrials.gov

A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 23, 2025

Primary Completion Date

October 31, 2028

Study Completion Date

October 31, 2032

Conditions
Retinitis Pigmentosa
Interventions
DRUG

DSP-3077 Retinal Sheet Cohort 1

For each participant only 1 eye will receive a low dose (\>= 0.8 to \< 2.4 mm2) of single subretinal injection of DSP-3077 using the DSP-3077-delivery device on Day 1

DRUG

DSP-3077 Retinal Sheet Cohort 2

For each participant only 1 eye will receive a high dose (\>= 2.4 to \< 6.4 mm2) of single subretinal injection of DSP-3077 using the DSP-3077-delivery device on Day 1

DRUG

DSP-3077 Retinal Sheet Cohort 3

For each participant only 1 eye will receive a high dose (\>= 2.4 to \< 6.4 mm2) of single subretinal injection of DSP-3077 using the DSP-3077-delivery device on Day 1

Trial Locations (1)

02114

RECRUITING

Massachusetts Eye and Ear, Boston

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY